Medios AG / Key word(s): Preliminary Results
26-Jan-2018 / 09:53 CET/CEST
Medios AG exceeds forecast for fiscal year 2017 – Management Board optimistic for fiscal year 2018
Berlin, 26 January 2018 – Medios AG has exceeded its forecast for the fiscal year 2017 due to stronger-than-expected growth. According to preliminary calculations (IFRS), the company’s consolidated sales revenue increased from January till December 2017 by 58 percent to EUR 253.0 million compared to the prior-year period (prior year EUR 160.4 million, pro-forma* IFRS). Earnings before taxes (EBT**) and special effects rose by 38 percent to EUR 8.0 million (prior year EUR 5.8 million, pro-forma* IFRS). The Management Board had expected a consolidated sales revenue amounting to EUR 230 million and an EBT before special effects amounting to EUR 7.0 million up to EUR 7.5 million.
The increase in consolidated sales revenue resulted essentially from gaining market share through the further expansion of the partner network as well as the extension of the product range in the Specialty Pharma field. The EBT takes into account negative impacts from growth investments and the prohibition of public tendering on cytostatic drugs as well as the effects of the new drug price regulation on oncological preparations. In contrast, the non-cash special effect through the stock option program, which was implemented on the basis of the resolution of the Annual General Meeting 2017 in order to incentivise the management team, is not taken into account. According to preliminary calculations, the special effect will cause an extraordinary expense amounting to around EUR 1.1 million in the fiscal year 2017.
For the fiscal year 2018, the Management Board is optimistic. A detailed forecast will be provided by Medios AG not later than April 2018 with the publication of the full consolidated financial statements 2017.
Matthias Gärtner, CFO Medios AG
* According to the securities prospectus dated 16 November 2016
Information and Explanation of the Issuer to this News:
About Medios AG
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Cautionary note regarding forward-looking statements/No duty to update
|Phone:||+49 30 232 566 – 800|
|Fax:||030 / 8321 8377|
|Listed:||Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf|
|End of Announcement||DGAP News Service|